The lawsuit says that the company, DaVita, used larger than necessary vials of medicine knowing that Medicare would pay for the unused portion of each vial if it were deemed unavoidable waste. DaVita, which treats nearly a third of the nation’s dialysis patients, denies the accusations.
The accusations are the latest related to how financial incentives may have driven overuse of pharmaceuticals in the dialysis business. In January, Medicare began a payment system that pays for the overall treatment and does not pay separately for the drugs accompanying it. Many practices, including the size of some vials used, suddenly changed, providing an instant case study of how financial incentives can influence treatment choices.
The lawsuit says that until January, for example, DaVita required nurses to use one 10-microgram vial of Zemplar, a vitamin D drug, instead of a six-microgram dose in three two-microgram vials,. It then billed Medicare for all 10 micrograms even though four went unused.
Instead of giving an entire 100-milligram vial of Venofer, an iron drug, once or twice a month, the clinics gave 25-milligram doses more frequently, the suit says. But since the drug came only in a 100-milligram vial, Medicare was billed for 100 milligrams for each dose, even though 75 milligrams were wasted, the lawsuit says.
The federal government investigated the claims for more than two years and decided in April not to join the lawsuit. The lawsuit, filed in October 2007, was then unsealed. The nurse and the doctor filed an amended complaint, with more data and evidence, on Monday in United States District Court in Atlanta.
Bill Myers, a spokesman for DaVita, said that the federal government’s decision not to pursue a case against his company suggested the accusations were weak. He also said that Medicare had approved the dosing plans but that he could not provide proof of that until it was presented in court.
Medicare, which pays for most dialysis treatments, used to reimburse clinics separately for the drugs they used. Clinics could make a profit because Medicare would pay slightly more than the clinics paid to buy the drugs.
In January, to deter overuse of drugs, Medicare instituted a new system in which it pays a fixed amount per treatment, including most of the drugs used. If the clinic can treat the patient for less than the amount paid by Medicare, it makes money; if not, it loses money.
This so-called bundled payment system has instantly turned drugs from a source of profit to a cost to be avoided. And dialysis clinics have responded.
Take Amgen’s Epogen, an anemia drug that is Medicare’s largest drug expenditure for dialysis. American clinics in the past have used far more of the drug than clinics in most other countries.
That high use possibly endangered patients because studies have shown that aggressive use of the drug can increase the risks of heart attacks and blood clots. But with the new payment system in place, clinics are using much less of the drug. Amgen’s sales of Epogen, all of which are for use in dialysis in the United States, decreased 14 percent in the first quarter of this year to $535 million. Analysts expect further declines.
In another example, new treatment guidelines now allow clinics to use less vitamin D than they once did.
Mr. Myers, the spokesman for DaVita, said the larger but fewer vials for Zemplar helped minimize needle sticks and protect patients and nurses from possible infection.
But giving Venofer, the iron drug, in smaller and more frequent doses would increase needle use, violating that policy. In the case of Venofer, Mr. Myers said, the small doses were thought to be better for the patient.
Article source: http://feeds.nytimes.com/click.phdo?i=bd45c758c70a1b8133aecb1c7f03d943
Speak Your Mind
You must be logged in to post a comment.